Form 4: Ovid Therapeutics Director Kevin Fitzgerald Acquires 90,000 Stock Options

Ovid Therapeutics director Kevin Fitzgerald was granted 90,000 stock options on December 12, 2024, which vest over 36 months.

Summary

• Kevin Fitzgerald, a director at Ovid Therapeutics, was granted 90,000 stock options on December 12, 2024.
• The options have an exercise price of $1.06 per share.
• These options will vest in 36 equal monthly installments, contingent on Mr. Fitzgerald's continued service with the company.
• The options expire on December 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between the director and the company. There are no negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the options is dependent on the future performance of Ovid Therapeutics' stock price.
• If the director leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The vesting of the stock options is contingent on the director's continued service with the company.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize and retain key personnel.
• The vesting schedule of 36 months is typical for such grants, aligning with long-term value creation.
• The exercise price of $1.06 is a common practice, often set at or near the market price at the time of the grant.

Stakeholder Impact

• The stock option grant may positively impact shareholder value if the director's performance contributes to the company's success.
• The vesting schedule encourages the director's long-term commitment to the company.

Key Dates

Keywords

stock options, Ovid Therapeutics, director, Kevin Fitzgerald, equity, vesting, insider trading, form 4